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Abstract 
 
Bacteremia refers to bacterial presence in the blood. Bacterial proliferation in the 
blood requires that the organism adapt its metabolism to available nutrients. 
Nucleotide precursors that could be used are present at low levels in the blood, and 
thus the invading bacteria must rely on de novo nucleotide biosynthesis for survival. 
The dihydroorotase domain is a key enzyme in pyrimidine biosynthesis and a 
promising drug target. The genes encoding the dihydroorotase (DHOase) and 
aspartate transcarbamoylase (ATCase) of Bacillus anthracis (B. anthracis) were 
cloned for expression in Escherichia coli (E. coli). The proteins were purified by affinity 
chromatography and the enzymatic activity was determined by enzyme assays. The 
data suggests that a physical and functional interaction exists. The activity of ATCase 
was increased by about 2 fold in the presence of an equimolar concentration of 
DHOase.  An ATCase-DHOase complex was formed as judged by S-300 gel filtration 
chromatography and cross-linking methods. Moreover, orotate was found to be an 
effective inhibitor of the DHOase activity at nanomolar concentrations. These results 
bring us closer to understanding the structural organization of the pyrimidine pathway 
in the pathogenic B. anthracis bacterium and provide a lead in the design of drugs 
selective to the bacteria.    
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1. Introduction 
 
1.1 Bacteremia  
The presence of bacteria in the bloodstream is referred to as bacteremia, a 
major cause of morbidity and mortality worldwide.[1, 2] The growth of bacterial 
pathogens in the blood represents one of the most dangerous stages of infection. The 
B. anthracis infection is characterized by the rapid growth of the bacteria in the host’s 
blood, reaching up to108 bacteria/ml.3 Bacteremia often leads to severe illness and 
death.   
While growing in the blood, bacteria do not only attempt to evade the immune 
response of the host, but also adjust their metabolism to suit the availability of 
nutrients.  For the proliferation of bacterial pathogens in human blood, bacteria need 
to synthesize metabolites that are present in limiting concentrations. For that, they 
need to produce specific enzymes that are critical for the growth of the bacteria in the 
bloodstream. Certain nutrients are scarce in the blood and need to be synthesized de 
novo by the proliferating bacteria in the blood.  E. coli is a major cause of Gram-
negative bacteremia in hospitalized patients.  A recent comprehensive, genome-wide 
search 4 for genes that are essential for growth in human serum showed that a 
majority of the mutants identified consistently carried a deletion of a gene involved in 
either the purine or pyrimidine nucleotide biosynthetic pathway.  
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The limited supply of nucleotide precursors appears to be the key limitation for 
bacterial growth in serum. Inactivation of genes involved in nucleotide biosynthesis led 
to significant growth defects in human serum not only for E. coli but also for 
Salmonella Typhimurium and 
B. anthracis. The study clearly 
shows that de novo nucleotide 
biosynthesis represents the 
single most critical metabolic 
need for bacterial growth in 
blood and is likely to be the 
only metabolic pathway that is 
indispensible for bacterial 
pathogens invading the blood.  
The corresponding enzymes 
involved in nucleotide 
biosynthesis are thus 
promising antibiotic targets for 
reducing bacterial growth and 
the treatment of bloodstream 
infections.   
More specifically, of the 
enzymes identified to be 
Figure 1: Genes involved in the purine and pyrimidine biosynthetic pathways. 
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essential for growth of pathogenic bacteria in human blood, two, PyrC and PurE, are 
especially attractive as targets for antibiotics. PyrC encodes dihydroorotase that 
catalyzes the reversible cyclization of carbamoyl aspartate to dihydroorotate in the 
third step of the pyrimidine biosynthesis pathway 5 (Figure 1).  
A detailed examination of PyrC and PurE gene products, as well as other 
enzymes of the nucleotide biosynthesis pathways, as potential antibiotic targets may 
ultimately lead to the development of new therapies for treatment of bacterial 
bloodstream infections. 
1.2 Anthrax 
Anthrax is a life-threatening infectious disease that is very often lethal.6 It can 
affect animals and humans and is caused by the bacterium Bacillus anthracis.  
Anthrax does not spread from person to person.  However, the disease can spread 
from diseased animals to humans by directly contacting the diseased animal or by 
food consumption of the infected animals.  Anthrax is spread by spores, such as via 
air inhalation, but does not spread directly from an infected animal or person to 
another.   
Anthrax organisms in the soil are dormant in the form of endospores or spores, 
which are difficult to destroy and able to survive in harsh and extreme conditions for a 
long period of time lasting as long as 48 years.  
Spores may reactivate and multiply rapidly upon inhalation, ingestion, or 
contact of spores with skin lesions on the host.  If anthrax spores are inhaled, they can 
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migrate and proliferate in the lymph glands in the chest area, leading to them 
spreading within the body.  Death is often the end result due to toxin production.    
  More recently, anthrax has received a lot of attention as its spores can be 
produced in vitro and used as a biological weapon.  Funding is available for anthrax 
research as the U.S. government largely lacks the range of medical countermeasures 
needed to protect citizens from anthrax and other potential bioweapons. 
Anthrax causes three forms of disease: cutaneous anthrax, inhalation anthrax, 
and gastrointestinal (bowel) anthrax. 
1.2.1 Cutaneous (skin) anthrax:  This form of anthrax most commonly results when 
humans handle the products of diseased animals.  It normally begins as a reddish 
spot that becomes enlarged and hardened.  Lymph glands present in the area may 
become swollen.  Symptoms can include muscle aches, pain, fever, and headaches.  
This form of anthrax is typically resolved in about six to seven weeks.  
 1.2.2 Inhalation anthrax:  The first symptoms are subtle, gradual, and flu-like and 
may develop in one to six days.  These may include sore throat, fever, and muscle 
pain.  However, in a few days, the illness worsens and may result in severe respiratory 
distress.  Shock, coma, and death may follow.  Even upon aggressive treatment, once 
severe symptoms develop, 45% to 80% of patients typically die, and if left completely 
untreated, the death rate can exceed 99%.     
1.2.3 Gastrointestinal anthrax: This form is rare.  It is caused by consumption of 
infected, contaminated, or undercooked meat.  The symptoms include nausea, bloody 
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diarrhea, loss of appetite, fever, and abdominal pain.  Once the anthrax bacteria 
invade the bowel wall, septicemia may result, where the infection spreads via the 
bloodstream throughout the body with deadly toxicity.   
 1.2.4 Antibiotic therapy:  Currently existing drugs are mainly effective if treatment is 
started early enough.  Common antibiotics such as penicillin, tetracycline, and 
ciprofloxacin, are used to treat the cutaneous form of anthrax.  Antibiotics delivered 
early via intravenous therapy are typically employed continuously for the pulmonary 
inhalation form.   
1.3 Bacillus Anthracis (B. anthracis) 
 B. anthracis is a spore-forming bacterium that can be grown under aerobic or 
anaerobic conditions.  It is a Gram-positive, rod-shaped bacterium that is about 1-
1.2µm wide and 3-5µm long.  It is the only bacterium, thus far, known to synthesize a 
protein capsule.  The spores of the bacteria are highly resilient and can survive and 
withstand low nutrient environments and extremes of temperatures for centuries.     
1.4 The Pyrimidine Biosynthetic Pathway 
Pyrimidine nucleotides play a critical role in cellular metabolism.  They serve as 
activated precursors of RNA and DNA, CDP-diacylglycerol phosphoglyceride for the 
assembly of cell membranes, and UDP-sugars for protein glycosylation and glycogen 
synthesis.  There are two routes to the synthesis of pyrimidines; nucleotides can be 
recycled by the salvage pathways or synthesized de novo from small metabolites. 
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Most cells have several specialized passive and active transporters that allow the 
reutilization of preformed pyrimidine nucleosides and bases.  
The de novo pyrimidine biosynthetic pathway (Figure 2) is indispensable in 
proliferating cells in order to meet the increased demand for nucleic acid precursors 
and other cellular 
components.  Pyrimidine 
biosynthesis is invariably up-
regulated in tumors and 
neoplastic cells and has 
been linked to the etiology or 
treatment of several other 
disorders including AIDS, 
diabetes, and autoimmune 
diseases, such as rheumatoid arthritis.  
1.4.1 Aspartate Transcarbamoylase (ATCase): ATCase catalyzes the reaction of 
carbamoyl phosphate and aspartate to form carbamoyl aspartate (Figure 2).  In 
mammalian cells, CAD is a multifunctional protein that catalyzes the first three steps of 
the pyrimidine biosynthetic pathway.  The carbamoyl phosphate synthetase (CPSase) 
domain catalyzes the first step in the pathway.  The ATCase domain is unregulated 
and catalyzes the second step in the pathway.  The isolated CAD ATCase domain is a 
homotrimer of 34-kDa subunits.7 Kinetic and modeling studies showed that the 
mammalian domain shares a common catalytic mechanism, oligomeric structure, and 
Figure 2:  The de novo pyrimidine biosynthesis pathway. 
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tertiary-fold with the E. coli ATCase catalytic subunit, (8-11) including a composite 
active site comprised of residues from adjacent subunits.  The trimeric ATCase 
interactions are a crucial organizing element in the CAD hexamer.  
 
 1.4.2 Dihydroorotase (DHOase): The DHOase domain catalyzes the third step in the 
pathway, the reversible condensation of carbamoyl aspartate to dihydroorotate (Figure 
2).  It is a zinc metalloenzyme.  The active site of E. coli DHOase has two zinc ions 
and a carboxylysine that bridges the metal centers.12 DHOases are classified 13 into 
two major classes.  Type I DHOases are the most ancient and include domains of 
multifunctional proteins, such as CAD, subunits of multienzyme complexes, and 
monofunctional enzymes. The type II enzymes, such as E. coli DHOase, are a more 
recent evolutionary development and are smaller in size.  The isolated CAD DHOase 
domain has only one zinc atom and is larger than its bacterial counterpart, consistent 
with its assignment as a type I DHOase.(14-17) The forward DHOase reaction is 
favored at low pH (below pH 6), and the reverse reaction is favored at high pH (above 
pH 8). 
1.5 B. anthracis DHOase  
The isolated DHOase from B. anthracis is a homodimer.18 The secondary 
structure of two chains is identical, with two zinc atoms in each chain and a total of 
180 water molecules.  An overall tertiary structure is formed from the TIM-barrel 
secondary structure motif.    
 
 
8 
The active site of the enzyme includes a binuclear Zn center.18 His59, His61, 
Asp151, and Asp304 are bound to the more buried α Zn atom while His178, His231, 
and Asp151 bind to the β Zn atom.  Asp151, via its carboxylate side group, forms a 
bridge between the two Zinc atoms, separated by 3.3 Å.  There is a large interface in 
the structure between the monomers, which involves 18 residues from one chain and 
17 residues from the other (Figure 3).     
  
 
 
 
 
 
Figure 3: Homodimer of the dihydroorotase from B. anthracis at 2.6 Å resolution
18
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1.6 Aquifex Aeolicus (A. aeolicus)   
A. aeolicus is a rod-shaped hyperthermophilic bacterium of ancient lineage.  It 
grows best in water between 85-95 ºC. It is found near volcanoes and hot springs.  
The genome of A. aeolicus is only about a third of that of E. coli.    
1.7 Sequence homology of B. anthracis and A. aeolicus DHOase 
The DHOase from B. anthracis is highly conserved in sequence to that of A. 
aeolicus. The percent sequence identity is 43% (Figure 4). 
 
Score =  321 bits (822),  Expect = 3e-89, Method: Compositional matrix adjust. 
 Identities = 182/426 (43%), Positives = 257/426 (61%), Gaps = 10/426 (2%) 
 
 
B. an  1    MNYLFKNGRYM----NEEGKIVATDLLVQDGKIAKVAENITADNAEVIDVNGKLIAPGLV  56 
            +  + KNG  +    N EG+    D+LV++GKI K+ +NI    AE+ID  G ++ PG + 
A. ae  2    LKLIVKNGYVIDPSQNLEGEF---DILVENGKIKKIDKNILVPEAEIIDAKGLIVCPGFI  58 
 
B. an  57   DVHVHLREPGGEHKETIETGTLAAAKGGFTTICAMPNTRPVPDCREHMEDLQNRIKEKAH  116 
            D+HVHLR+PG  +KE IE+G+  A  GGFTTI  MPNT P  D    +  +  + K     
A. ae  59   DIHVHLRDPGQTYKEDIESGSRCAVAGGFTTIVCMPNTNPPIDNTTVVNYILQKSKSVGL  118 
 
B. an  117  VNVLPYGAITVRQAGSEMTDFETLKELGAFAFTDDGVGVQDASMMLAAMKRAAKLNMAVV  176 
              VLP G IT  + G E+ DF +LKE G  AFTDDG  V D+S+M  A++ A++L + ++ 
A. ae  119  CRVLPTGTITKGRKGKEIADFYSLKEAGCVAFTDDGSPVMDSSVMRKALELASQLGVPIM  178 
 
B. an  177  AHCEENTLINKGCVHEGKFSEKHGLNGIPSVCESVHIARDILLAEAADCHYHVCHVSTKG  236 
             HCE++ L   G ++EG+ S   GL+      E + IARD +LA+    H H+ HVSTK  
A. ae  179  DHCEDDKL-AYGVINEGEVSALLGLSSRAPEAEEIQIARDGILAQRTGGHVHIQHVSTKL  237 
 
B. an  237  SVRVIRDAKRAGIKVTAEVTPHHLVLCEDDIPSADPNFKMNPPLRGKEDHEALIEGLLDG  296 
            S+ +I   K  G+K+T EV P+HL+  E ++ ++  N ++NPPLR KED  ALIEG+  G 
A. ae  238  SLEIIEFFKEKGVKITCEVNPNHLLFTEREVLNSGANARVNPPLRKKEDRLALIEGVKRG  297 
 
B. an  297  TIDMIATDHAPHTAEEKAQGIERAPFGITGFETAFPLLYTNLVKKGIITLEQLIQFLTEK  356 
             ID  ATDHAPH   EK + +E A  GI G +TA P     L +KGII+L++LI+  T   
A. ae  298  IIDCFATDHAPHQTFEK-ELVEFAMPGIIGLQTALPSAL-ELYRKGIISLKKLIEMFTIN  355 
 
B. an  357  PADTFGLEAGRLKEGRTADITIIDLEQEEEIDPTTFLSKGKNTPFAGWKCQGWPVMTIVG  416 
            PA   G++ G LK G  ADITI D  +E  ++  T LSK +NTP  G   +G  + TI   
A. ae  356  PARIIGVDLGTLKLGSPADITIFDPNKEWILNEETNLSKSRNTPLWGKVLKGKVIYTIKD  415 
 
B. an  417  GKIAWQ  422 
            GK+ ++ 
A. ae  416  GKMVYK  421 
                     
                             Figure 4: Sequence homology of B. Anthracis and A.aeolicus DHOase 
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1.8 DHOase from A. aeolicus  
Unlike the DHOase from E. coli and B. anthracis, the DHOase from A. aeolicus 
has a single zinc ion (Figure 5) present only in the α site.  Moreover, the structure has 
three disordered surface loops near the active site and a complete composite domain 
involving both N-terminal and C-terminal segments.19   
 
 
 
 
 
 
 
The isolated A. aeolicus DHOase domain is catalytically inactive (Figure 5) despite the 
presence of the zinc and all of the active site residues needed for catalysis.  That 
activity is completely regained, however, upon association with A. aeolicus ATCase.  
A 1:1 stoichiometric complex of A. aeolicus DHOase and ATCase can be reconstituted 
and is fully active.19 
 
Figure 5:  Three-dimensional structure and active site of A. aeolicus DHOase 
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Both the DHOase and ATCase monomers are inactive.  A mode for the 
complex formation may be that the ATCase associates form a catalytically active 
trimer, which then associates with the DHOase monomers to form a hexamer that has 
both DHOase and ATCase activities (Figure 6).  
The 1:1 stoichiometric complex was found to exist as an equilibrium mixture of 
(ATCase)3(DHOase)3 hexamers and ((ATC)3(DHOase)3)2 dodecamers.
19  
Significantly, the DHOase component, as well as the ATCase, in the complex is 
catalytically active. 
    Interestingly, while the DHOase appears to rely on the ATCase for its catalytic 
activity, the converse does not appear to be true as the A. aeolicus ATCase is not 
activated by DHOase.  
 
Figure 6: Model for the assembly of the A. aeolicus DHOase-ATCase complex. 
 
 
12
1.9 A stoichiometric complex (DAC) of A. aeolicus DHOase and ATCase 
  A stoichiometric complex of A. aeolicus DHOase forms with ATCase in a 
hollow, hetero-dodecamer (Figure 7), in which all 12 enzyme active sites face an 
aqueous cavity with limited access to the exterior.  This amazing architecture may 
facilitate allosteric communication between the active sites and possibly increases the 
net production of dihydroorotate, which is thermodynamically unfavored at 
physiological pH.  
The three active site loops that are intrinsically disordered in the free, inactive 
DHOase, described above, are ordered in the DAC complex. 
 
  
 
 
 
 
 
 
 
                         
   
 
Figure 7: The DAC dodecamer 
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2. Research Goal and Objectives 
The overall goal of this research work is to more thoroughly characterize the 
second and third steps in de novo pyrimidine biosynthesis in B. anthracis and to gain a 
better understanding of the structural and functional organization of the B. anthracis 
ATCase and DHOase domains.   
2.1 Significance of the Proposed Study 
The DHOase has recently emerged as a promising drug target that may 
ultimately lead to new therapies and pave the way for structure-based drug discovery 
for treatment of Anthrax and other bacterial bloodstream infections.   
2.2 Hypothesis 
Anthrax ATCase and DHOase physically interact to form a dodecamer that 
resembles that of A. aeolicus in structure and function.  
2.3 Specific aims/goals 
1) Identify whether the B. anthracis DHOase and ATCase form a physical complex. 
This can be investigated by cross-linking and by determining the oligomeric structure 
of the individual proteins and their mixtures by gel filtration chromatography.  The 
fractions can be collected from the column and analyzed by SDS-PAGE.  Enzyme 
activities will be determined by enzyme assays. 
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2) Explore the putative functional interactions of ATCase and DHOase.  The proteins 
will be mixed in different stoichiometric ratios and their activities measured by the 
corresponding enzyme assays.   
     
3) Study the effect of inhibitors previously used for the mammalian system, such as 
Orotate, 5-amino-orotic acid, and 5-fluoro-orotic acid.  Enzyme assays will be carried 
out in the presence and absence of inhibitors.                                
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3. Methods and Materials 
 
3.1 Materials 
Reagents including aspartate, carbamoyl aspartate, dihydroorotate, antipyrine, 
diacetyl monoxime, carbamoyl phosphate used for enzyme assays, High Resolution 
Sephacryl S-300 used for gel filtration chromatography, and the antibiotic ampicillin, 
were all purchased from Sigma-Aldrich.  The bacterial strain, BL21 (DE3), used for 
expression of recombinant proteins and the bench mark prestained protein ladder, 
were from Invitrogen.   
 
3.2 Expression and Isolation of the Recombinant Proteins 
Plasmid DNA encoding B. anthracis ATCase and DHOase were transformed 
separately into the E. coli strain BL21 (DE3). The transformants were grown on agar 
plates containing ampicillin.  A single colony was selected and grown at 37 °C in an 
overnight 15-ml culture consisting of LB medium and 100 µg/ml ampicillin. The 
overnight culture was then inoculated into a 125-ml LB medium containing 100 µg/ml 
of ampicillin and grown at 37oC. The cells were harvested and the pellet was 
resuspended in 3 ml of 50 mM Tris/HCl, pH 8. The cells were disrupted by sonication 
for 30 s in an ice/water bath for a total of five times with five minutes intervals to 
prevent overheating. The cell extract was centrifuged at 14,000 rpm for 30 min at 4 
°C, and the supernatant from the centrifuged fractions was collected and loaded onto 
a 1-ml Ni2+-ProBond column equilibrated with 20 ml of 50 mM Tris/HCl, pH 8, 200 
mM NaCl (TN buffer).  The B. anthracis ATCase and DHOase were eluted with 
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successive 3-ml aliquots of increasing concentrations of imidazole up to 300 mM in TN 
buffer. The fractions were collected and analyzed by electrophoresis on 12% SDS-
PAGE gels and by enzyme activity assays. 
 
3.3 ATCase Assay 
The ATCase activity was determined by measuring the time dependent formation of 
carbamoyl aspartate from carbamoyl phosphate and aspartate. 
 
         Carbamoyl phosphate          Carbamoyl aspartate 
             ATCase, Asp 
The assay mixture consisted of 2 mM aspartate, 50 mM Tris/acetate buffer, pH 8.3, 
and 2-3 µg of purified ATCase in a total volume of 1 ml.  Samples were allowed to 
preincubate at 37°C for 20 min. The reaction was then initiated by the addition of 
100µl of 50 mM carbamoyl phosphate at 37oC and allowed to proceed for 10 min. The 
reaction was then quenched with 1 ml of 5% acetic acid. A 2ml color mix which 
contains antipyrine/diacetyl monoxime was added to generate a yellow color and the 
assay mixture was heated at 60°C for 30-90 min for color development.  The 
carbamoyl aspartate generated by ATCase is converted into a yellow- colored 
compound, and the absorbance was measured at 466 nm on a spectrophotometer.  
 
3.4 DHOase Assay 
The DHOase assay measured the reverse reaction, formation of carbamoyl aspartate 
from dihydroorotate, as the equilibrium strongly favors dihydroorotate hydrolysis under 
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the assay conditions. The formation of carbamoyl aspartate was quantitated at 466 
nm, as described above.   
         Carbamoyl aspartate                   dihydroorotate 
                                                                  DHOase 
The assay mixture consisted of 2-3 µg of purified DHOase, 50 mM Tris/acetate, pH 
8.3, and 10% glycerol, in a total volume of 1ml. The tubes were preincubated for 20 
min at 37°C.  The reaction was then initiated with 80 mM dihydroorotate and 
quenched after 10 min of assay reaction by the addition of 1 ml 5% acetic acid.  A 
color mix consisting of 2 ml of the diacetyl monoxime/antipyrine reagent was added 
and the assay mixture heated at 60 °C for 30-90min to generate a yellow color.  The 
samples were briefly cooled and the absorbance measured at 466 nm. 
3.5 Formation of the ATCase-DHOase Complex 
The complex was prepared by mixing ATCase and DHOase in 1:1 mole-mole ratio 
followed by incubation on ice for 1 hr with gentle mixing. 
3.6 Gel Filtration Chromatography 
Proteins were eluted by size exclusion chromatography in decreasing order of size.  
The oligomeric structure of the individual enzymes and the possible interaction 
between them can be investigated using this technique.  A 1.5 × 62 cm or 1.5 ×120 
cm high resolution Sephacryl S-300 column was used in this study.  Column beads 
were cleaned with 0.5M NaOH for 2hr then equilibrated with 50mM Tris/acetate buffer, 
pH 8.3.  The flow rate of the column was 0.25 ml/min.  Isolated ATCase or DHOase 
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(0.6 ml, of 2-3 mg/ml) or mixed (0.6 ml, of 2-3 mg/ml) in an equimolar ratio were 
loaded onto the column and allowed to flow through the column at a rate of 0.25 
ml/min.  The fractions were collected and analyzed by 12% SDS-PAGE gel 
electrophoresis and by enzyme assays. 
3.7 Inhibition Studies 
5-amino orotic acid, orotic acid, and 5-fluro orotic acid were used as inhibitors of the 
DHOase activity.   
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4. Results and Discussion 
 
4.1 Expression of B.  Anthracis Proteins 
Plasmids encoding the B. anthracis proteins were expressed in E. coli BL21 (DE3) 
and the expressed proteins purified by affinity chromatography.  Proteins were applied 
to a Ni2+ affinity chromatography resin and eluted with different imidazole 
concentrations. The fractions were analyzed for protein purity using SDS-PAGE.  
Purified B. anthracis ATCase and DHOase were typically obtained in the 200 mM 
imidazole/TN buffer (Figure 8). The purity of DHOase, 48 kDa, eluted with 200 mM 
imidazole, was judged greater than 90% by SDS-PAGE. The concentration of the 
purified protein, determined by the Lowry assay, ranged between 0.5 - 2.0 µg/µl. 
 
 
 
 
 
 
 
 
 
 
 
Anthrax DHOase
Expression and Affinity Chromatography
L      Su FT      W1 W2 I50 I100 I200 I300 I400
115 kDaà
180 kDaà
64 kDaà
82 kDaà
49 kDaà
37 kDaà
26 kDaà
19 kDaà
15 kDaà
DHOase
48 KDa
Figure 8:  SDS-Page of B. anthracis DHOase expression and 
purification by Ni2+ affinity chromatography. Purified DHOase, 
48 kDa, was eluted with 200 mM imidazole (I200). 
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Purified B. anthracis ATCase (Figure 9), 36 kDa, was eluted with 200 mM 
imidazole.  The concentration of the protein ranged between 0.5- 2.0 µg/µl as 
determined by the Lowry assay using BSA as the standard.  
 
 
 
 
 
 
 
 
 
 
 
 
4.2 Enzymatic Assay of DHOase 
The activity of DHOase (Figure 10) was determined by measuring the formation of 
carbamoyl aspartate at 37oC. The biosynthetic conversion of N-carbamoyl-L-aspartate 
to dihydro-L-orotate was also measured spectrophotometrically.  The concentration of 
carbamoyl aspartate was calculated from a standard curve of known concentrations of 
carbamoyl aspartate.  The 1-ml reaction mixture contained 50 mM Tris/acetate, pH 
8.3, 1% glycerol, varying concentrations of dihydroorotate and 4.8 µg purified 
DHOase.  The reaction mixture was pre-equilibrated for 20 min at 37oC and then 
Anthrax ATCase
Expression and Affinity Chromatography
L      So          Su     FT          W1 W2 I50 I100 I200 I300
64 kDaà
82 kDaà
115 kDaà
180 kDaà
49 kDaà
37 kDaà
26 kDaà
19 kDaà
15 kDaà
ATCase
36 KDa
Figure 9: SDS-Page of B. anthracis ATCase expression and purification 
by Ni2+ affinity chromatography. Purified ATCase, 36 kDa, was eluted with 
200 mM imidazole (I200).   
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initiated by the addition of the substrate dihydroorotate or protein and quenched with 
5% acetic acid after 20 min reaction time. A 2 ml color mix which contained a 1:2 
(volume: volume) ratio of diacetyl monoxime and antipyrine was then added, and the 
tubes were incubated at 60°C for 30-90 min for yellow color development.  The 
absorbance was measured at 466 nm. The linear increase in absorbance due to the 
formation of carbamoyl aspartate from dihydroorotate was followed.  The equilibrium 
strongly favors dihydroorotate hydrolysis. 
 
               
 
 
 
 
 
 
 
 
 
 
4.3 Enzyme Assay of ATCase 
The ATCase activity (Figure 11) was determined by measuring the formation of 
carbomyl aspartate from carbamoyl phosphate and aspartate.  The 1 ml assay 
reaction consisted of 2 mM aspartate, 50 mM Tris/acetate, pH 8.3, 1% glycerol, 5 mM 
  Dihydroorotate (mM) 
   
   
µm
ol
/m
in
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Figure 10: Dihydroorotate saturation curve of isolated B. anthracis 
DHOase.  
 
 
 
22
carbamoyl phosphate, and 2 µg of purified protein.  The reaction mixture was pre-
warmed for 20 min at 37oC and then initiated with either the protein or the substrate, 
carbamoyl phosphate. The reaction was allowed to proceed for 20 min and was then 
quenched with 1 ml 5% acetic acid.  After the reaction was quenched, a 2 ml color mix 
consisting of a 1:2 (volume: volume) ratio of diacetylmonoxime and antipyrine was 
added and the mixture incubated at 60°C for 30-90 min for color development. The 
absorbance was then measured spectrophotometrically at 466 nm and the amount of 
carbamoyl aspartate formed calculated from the carbamoyl aspartate standard curve.  
The free Bacillus anthracis ATCase is active by itself. The increased information of 
carbamoyl aspartate from Carbamoyl phosphate was followed.                                                   
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Figure 11: ATCase enzymatic assay of as a function of increasing concentrations of 
the protein.   
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4.4 Investigating Functional Interactions of the DHOase and ATCase Domains of 
B. anthracis 
The isolated B. anthracis ATCase is catalytically active as is the isolated 
DHOase domain.  Functional interactions among domains involved in pyrimidine 
biosynthesis have been documented in several systems that include that found in 
Aquifex aeolicus.19 Therefore, to investigate whether the B. anthracis ATCase and 
DHOase domains may influence each other through functional interactions, assays of 
ATCase and DHOase were carried out in the presence of both proteins.    
4.4.1: Effect of DHOase on the ATCase Activity:  The ATCase and DHOase were 
mixed in 1:1 molar ratio and incubated on ice for 1hr. The activity of ATCase (Figure 
12) in the absence or presence of DHOase was determined by measuring the 
formation of carbomyl aspartate from carbamoyl phosphate and aspartate as 
described above.  The ATCase activity appears to be increased by nearly 2-fold in the 
presence of DHOase in a linear fashion. 
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Figure 12: ATCase assay of the B. anthracis ATCase in the absence or in the 
presence of equimolar B. anthracis DHOase.  The ATCase activity is increased in 
the presence of DHOase.   
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          ATCase assays as a function of increasing carbamoyl phosphate (CP) 
concentrations were also carried out (Figure 13).  The final concentrations of CP in the 
reaction tubes were 0 mM, 0.5 mM, 1 mM, 2 mM, 3 mM, 4 mM, and 5 mM.  The 
reaction mixtures were allowed to pre-incubate for 20 min at 37oC and then initiated 
with 10µl of (0.72 µg/µl) ATCase protein and, in parallel reactions, with an equimolar 
concentration of ATCase and DHOase. The reactions were allowed to proceed for 20 
min then quenched with 1ml 5% acetic acid, and the absorbance read at 466 nm, as 
described above.   
 
 
 
 
 
 
 
 
 
 
Addition of B. anthracis DHOase resulted in an apparent two-fold activation of 
B. anthracis ATCase, suggesting a functional linkage between the two enzymes.  
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Figure 13: ATCase assay as a function of increasing carbamoyl phosphate 
(CP) concentrations of B. anthracis ATCase in the absence (◊) and in the 
presence of B. anthracis DHOase (□). 
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4.4.2: B. anthracis DHOase Activates B. anthracis ATCase in a 1:1 mole/mole 
ratio: A fixed concentration of ATCase (0.86 µg/µl) was titrated with different 
concentrations of DHOase (0.60 µg/µl) (DHOase/ATCase: 1:10, 5:10, 10:10, 20:10, 
40:10, 60:10, 100:10) in order to find the amount of DHOase needed to activate the 
ATCase.   The enzyme activity at different protein ratios were assayed as well as 
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ATC (nmol)   5                1               1              1              1             1               1                       0 
 
 
DHO (nmol)   0               0              0.05        0.25          0.5           1               4                       5 
Figure 14: SDS-PAGE gel and ATCase enzyme assay with a fixed B. anthracis ATCase concentration and 
increasing concentrations of B. anthracis DHOase. 1 mole of the DHOase was required to achieve maximal 
activation of 1 mole of ATCase.  The points on the assay and gel corresponding to an equimolar concentration 
of both proteins are boxed.   
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visualized by SDS-PAGE (Figure 14). The ATCase activity increases with increasing 
concentrations of DHOase and stabilized until the DHOase and ATCase 
concentrations were equimolar.  Addition of increasing molar concentrations of 
DHOase did not result in further activation.   
 
4.5 A. aeolicus DHOase Weakly Activates B. anthracis ATCase 
 The finding that the B. anthracis ATCase is optimally activated by equimolar 
concentrations of B. anthracis DHOase suggests a functional interaction between the 
two proteins.  To investigate the specificity of this interaction, A. aeolicus DHOase, 
which has a high sequence similarity to B. anthracis DHOase, was added at various 
molar ratios (Figure 15) to B. anthracis ATCase to examine its ability to activate the 
enzyme.  A. aeolicus DHOase was able to activate the ATCase from B. anthracis but 
much more weakly than the DHOase from B. anthracis.  While it took 1 mole of B. 
anthracis DHOase to fully activate the ATCase (Figure 14), the enzyme was activated 
by only 50% at 25 moles of A. aeolicus DHOase per 1 mole of ATCase.  Moreover, full 
activation of B. anthracis ATCase required 50 moles of A. aeolicus DHOase.  These 
results suggest that optimal activation of B. anthracis ATCase is achieved by specific 
interactions with B. anthracis DHOase.  These interactions appear not to be 
conserved in the A. aeolicus enzyme.    
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4.5.1 Effect of ATCase on DHOase:  The DHOase activity of B. anthracis DHOase 
was assayed (Figure 16) in the absence or presence of equimolar B. anthracis 
ATCase to investigate putative functional interactions between the two domains.  The 
isolated B. anthracis DHOase was found to be catalytically active in the absence of B. 
anthracis ATCase, a situation that differs remarkably from that of A. aeolicus, in which 
the isolated DHOase is only active in the presence of the A. aeolicus ATCase 
domain.19 Interestingly, the B. anthracis DHOase does not appear to be affected by 
the presence of B. anthracis ATCase under these conditions.   
DHO (nmol)  0               0               4             10           15           25           50            50 
 
ATC (nmol)   5               1               1              1              1            1             1              0 
 
Figure 15: ATCase activity and SDSPAGE of a fixed concentration of B. anthracis ATCase and different 
concentrations of A. aeolicus DHOase. A. aeolicus DHOase weakly activates B. anthracis ATCase as 
compared to B. anthracis DHOase.  The boxed lane on the SDS-gel corresponds to the boxed point on 
the assay curve.     
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4.6: B. anthracis ATCase cannot activate A. aeolicus DHOase  
The ATCase from B. anthracis shares a high sequence similarity with the 
ATCase from A. aeolicus.  The isolated A. aeolicus DHOase is completely inactive 
and needs associations with the A. aeolicus ATCase to become catalytically active.  
To investigate the specificity of the interactions in B. anthracis, we wanted to examine 
whether the A. aeolicus DHOase can be activated by the ATCase from B. anthracis. 
 
A dihydroorotate saturation curve was carried out (Figure 17) to assay for the 
activity of isolated A. aeolicus DHOase in the absence or presence of stoichiometric 
amounts of A. aeolicus ATCase and B. anthracis ATCase.   
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Figure 16: A dihydroorotate saturation curve of B. anthracis DHOase in the absence 
or presence of equimolar B. anthracis ATCase.  No stimulation of activity is apparent 
in the presence of B. anthracis ATCase under these conditions. 
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As expected and in accord with previous findings,19 isolated A. aeolicus 
DHOase assayed alone showed no catalytic activity unless in the presence of A. 
aeolicus ATCase.  Interestingly, B. anthracis ATCase was not able to activate the A. 
aeolicus DHOase despite its high sequence identity with the A. aeolicus ATCase.   
 
  These results clearly show that B. Anthracis ATCase is activated by 
stoichiometric amounts of B. anthracis DHOase, while the DHOase is not activated by 
ATCase under these assay conditions.  The reverse is observed in the A. aeolicus 
system.  The ATCase domain is not activated by the DHOase, and the isolated A. 
aeolicus DHOase is completely inactive in the absence of ATCase despite the 
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Figure 17: DHOase assay as a function of increasing 
dihydroorotate concentration of A. aeolicus DHOase alone (♦), in 
the presence of A. aeolicus ATCase (■) or in the presence of B. 
anthracis ATCase (▲). 
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presence of all the active site residues and metal binding residues needed for 
catalysis.   
 
These interactions appear to be highly specific.  As mentioned above, the A. 
aeolicus DHOase has a high sequence similarity with that of B. Anthracis DHOase 
with a percent sequence identity of 43%.  However, despite the high sequence 
similarity, A. aeolicus DHOase only weakly activated the ATCase from B. anthracis.  
Moreover, despite the high sequence similarity of the ATCase from A. aeolicus and B. 
anthracis, the B. anthracis ATCase failed to activate the A. aeolicus DHOase.   
 
4.7 Inhibitor Assays 
An important objective of studying the B. anthracis pyrimidine enzymes is the 
development of drugs that can selectively inhibit the bacterial pathway with minimum 
or no effect on the mammalian pathway.  The purified DHOase from B. anthracis was 
assayed with known inhibitors of DHOases from other organisms: 5-amino orotic acid, 
orotic acid, and 5-fluroorotic acid (Figure 18).  The assays show that orotate was able 
to inhibit B. anthracis DHOase at nanomolar concentrations.  However, as orotate is 
the product of the next enzyme in the pathway, dihydroorotate dehydrogenase (Figure 
2), modified compounds that resemble orotate need to be designed to more 
selectively inhibit the dihydroorotase domain, a domain clearly found to be 
indispensible for the B. anthracis bacterial growth. 
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4.8 Gel Filtration Chromatography 
B. anthracis ATCase, 0.6 ml (0.5 mg) was applied onto an S-300 Sephacryl gel 
filtration column, and the protein was eluted with a buffer consisting of 50 mM 
Tris/acetate, pH 8.0, 200 mM sodium chloride, and 10% glycerol.  Fractions (1 ml) 
each were collected and analyzed by SDS-PAGE.  Fractions corresponding to the 
peak (Figure 19) were tested for enzymatic activity. The peak fractions, lanes 4-6, 
Figure 18: Inhibition assays of B. anthracis DHOase 
B. anthracis 
ATCase is a 
trimer 
 
Lane:             1                   2               3                 4                 5                6                   7                8 
 
Figure 19:  S-300 gel filtration chromatography fractions of B. anthracis ATCase  
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showed the highest ATCase activity.   
B. anthracis DHOase, 0.6 ml (0.75 mg) was applied to a S-300 Sephacryl gel 
filtration column and eluted with a buffer consisting of 50 mM Tris/acetate, pH 8.0, 200 
mM sodium chloride, and 10% glycerol (Figure 20).  Fractions corresponding to the 
peak (Figure 20) were tested for enzymatic activity. The peak fractions, lanes 2-6, 
showed the highest DHOase activity.   
 
A stoichiometric mixture of ATCase and DHOase (0.6 ml) was preincubated at 
room temperature for 20 min and then loaded onto the S-300 gel filtration column.  
The proteins were eluted in a buffer consisting of 50 mM Tris/acetate, pH 8.0, 200 mM 
sodium chloride, and 10% glycerol.  The fractions were then analyzed using SDS-
PAGE (Figure 21).  Fractions corresponding to the peak (4-7) had both ATCase and 
DHOase activities.  The two proteins eluted in the same fractions, suggesting 
formation of a complex most likely to be a dodecamer consisting of 2 ATCase trimers 
and 3 DHOase dimers.  This complex likely resembles that found in A. aeolicus.    
B. anthracis 
DHOase is a 
homodimer 
 
Lane:        1                    2                   3                   4                 5                6                   7 
 
Figure 20: S-300 gel filtration chromatography fractions of B. anthracis DHOase 
B. anthracis 
ATCase and 
DHOase is likely 
a dodecamer 
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Figure 21: S-300 gel filtration chromatography fractions of B. anthracis DHOase and ATCase 
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                                              5. Summary 
1) S-300 Sephacryl gel filtration chromatography suggests that a complex, likely a 
dodecamer, is formed between B. anthracis ATCase and DHOase. 
2) Enzyme assays showed that B. anthracis ATCase and B. anthracis DHOase 
are active individually and that they do not depend on each other for catalytic 
activity.  
3) In a stoichiometric complex between B. anthracis ATCase and B. anthracis 
DHOase, DHOase appears to activate ATCase by nearly twofold, while 
ATCase does not appear to further activate the DHOase.   
4) The opposite effect is found in the analogous A. aeolicus system where the 
DHOase is completely inactive unless associated with the ATCase domain and 
where the ATCase activity is not stimulated by DHOase.  This is despite the 
high sequence identity between the two enzymes in the two systems.    
5) A. aeolicus DHOase can activate B. anthracis ATCase, albeit very weakly.   
Much higher molar ratios are required for the observed effects.  These results 
support the specificity of the interactions between the enzymes in the same 
system.   
6) Orotate inhibits the B. anthracis DHOase at nanomolar levels.  This finding sets 
the stage for the development of drugs that can mimic orotate and selectively 
inhibit the B. anthracis DHOase.    
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6. Future Studies 
Determining the three dimensional structure of the B. anthracis DHOase-
ATCase complex will provide invaluable information of the overall structure and a 
close-up view of the active sites.  The information obtained will shed light on the 
specific functional interactions between the two proteins and aid in the design of 
specific inhibitors that will likely result in the development of new therapeutic 
approaches to infections resulting from the bacteria, B. anthracis.   
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